Paper Citing NAMD - Abstract
Mendoza-Martinez, Cesar; Correa-Basurto, Jose; Nieto-Meneses, Rocio; Marquez-Navarro, Adrian; Aguilar-Suarez, Rocio; Dinora Montero-Cortes, Miriam; Nogueda-Torres, Benjamin; Suarez-Contreras, Erick; Galindo-Sevilla, Norma; Rojas-Rojas, Angela; Rodriguez-Lezama, Alejandro; Hernandez-Luis, Francisco
Design, synthesis and biological evaluation of quinazoline derivatives as anti-trypanosomatid and anti-plasmodial agents
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 96:296-307, MAY 26 2015
In this paper, the design, synthesis and biological evaluation of a set of quinazoline-2,4,6-triamine derivatives (1-9) as trypanocidal, antileishmanial and antiplasmodial agents are explained. The compounds were rationalized basing on docking studies of the dihydrofolate reductase (DHFR from Trypanosoma cruzi, Leishmania major and Plasmodium vivax) and pteridin reductase (PTR from T. cruzi and L major) structures. All compounds were in vitro screened against both bloodstream trypomastigotes of T cruzi (NINOA and INC-5 strains) and prornatigotes of Leishmania mexicana (MHOM/BZ/61/M379 strain), and also for cytotoxicity using Vero cell line. Against T. cruzi, three compounds (5, 6 and 8) were the most effective showing a better activity profile than nifurtimox and benznidazole (reference drugs). Against L. mexicana, four compounds (5, 6, 8, and 9) exhibited the highest activity, even than glucantime (reference drug). In the cytotoxicity assay, protozoa were more susceptible than Vero cells. In vivo Plasmodium berghei assay (ANKA strain), the compounds 1, 5, 6 and 8 showed a more comparable activity than chloroquine and pyrimethamine (reference drugs) when they were administrated by the oral route. The antiprotozoal activity of these substances, endowed with redox properties, represented a good starting point for a medicinal chemistry program aiming for chemotherapy of Chagas' disease, leishmaniosis and malaria. (C) 2015 Elsevier Masson SAS. All rights reserved.
